Reinventing Flexion For The World Beyond Proof-Of-Concept
Executive Summary
Flexion Therapeutics had the pedigree, determination, and corporate connections to source and speed to clinical proof-of-concept its in-licensed pharma assets, and it planned to build a business around getting paid to do so. But a funny thing happened on the way to the bank.
You may also be interested in...
BioMotiv: An Rx For Asset Financing Without The Venture Headache
Backed by a Cleveland family foundation and powerful hospital group, the for-profit BioMotiv wants to do biopharma asset financing on its own terms.
Versant Ventures Looks To Canada, Europe For New Deals
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”
No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials
Now focused on two key programs in its osteoarthritis portfolio, the Massachusetts drug developer will align itself for a more traditional exit rather than a Big Pharma partnership.